Concerns about nitrosamine impurities led the US Food and Drug Administration on 1 April to request immediate withdrawal of all prescription and over-the-counter ranitidine drugs, commonly known as Zantac, from the US market, and to ask pharmaceutical companies to check for similar risks in their other drug products.
The agency plans to provide guidance soon on how it expects manufacturers to assess the risk of nitrosamine formation in all their drug products. EU regulators imposed a similar requirement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?